Extending the Use of Atezolizumab and Bevacizumab to a Liver Transplant Recipient: Need for a Posttransplant Registry

Liver Transpl. 2021 Jun;27(6):928-929. doi: 10.1002/lt.26011.

Authors

Najib Ben Khaled¹, Daniel Roessler¹, Florian P Reiter¹, Max Seidensticker², Markus Guba³, Enrico N De Toni¹

Affiliations

¹ Department of Medicine IIUniversity Hospital, Ludwig Maximilians University MunichMunichGermany.
² Department of RadiologyUniversity Hospital, Ludwig Maximilians University MunichMunichGermany.
³ Department of General-, Visceral- and Transplantation-SurgeryUniversity Hospital, Ludwig Maximilians University MunichMunichGermany.

PMID: 33570764
DOI: 10.1002/lt.26011

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Bevacizumab / adverse effects
Biology
Carcinoma, Hepatocellular*
Humans
Liver Neoplasms* / drug therapy
Liver Transplantation*
Living Donors
Neoplasm Recurrence, Local
Patient Selection
Registries

Substances

Antibodies, Monoclonal, Humanized
Bevacizumab
atezolizumab